---
title: "Goldman Sachs, UnitedHealth And A Tech Stock On CNBC’s ‘Final Trades’"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299452722.md"
description: "On CNBC’s 'Final Trades,' Kevin Simpson selected UnitedHealth Group ahead of its Q3 earnings release, with analysts expecting $4.14 EPS on $111.49B revenue. Malcolm Ethridge chose Goldman Sachs, supported by an HSBC upgrade and raised price target to $995. Joseph Terranova recommended Teradyne, citing better-than-expected Q2 results and strong guidance. Stock performance showed UnitedHealth flat, Goldman Sachs up 1.4%, and Teradyne surging 3.5%."
datetime: "2026-09-18T13:05:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299452722.md)
  - [en](https://longbridge.com/en/news/299452722.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299452722.md)
generator: "portal-rs"
---

# Goldman Sachs, UnitedHealth And A Tech Stock On CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” **Kevin Simpson**, founder and CEO of Capital Wealth Planning, picked **UnitedHealth Group Incorporated** (NYSE:UNH).

UnitedHealth Group said it will release its third-quarter financial results on Tuesday, Oct. 13, before the opening bell. Analysts expect the company to report quarterly earnings at $4.14 per share on revenue of $111.49 billion.

**Malcolm Ethridge**, managing partner at Capital Area Planning Group, named **The Goldman Sachs Group, Inc.** (NYSE:GS) as his final trade.

Lending support to his choice, HSBC analyst Saul Martinez, on July 21, upgraded Goldman Sachs from Reduce to Hold and raised the price target from $834 to $995.

*Don’t forget to check out our premarket coverage here* 

**Joseph M. Terranova**, senior managing director for Virtus Investment Partners, recommended **Teradyne, Inc.** (NASDAQ:TER).

On the earnings front, Teradyne reported better-than-expected second-quarter results on July 28 and issued stronger-than-expected guidance for the current quarter.

The company reported adjusted earnings of $2.47 per share, topping the analyst consensus estimate of $2.09. Revenue more than doubled from a year earlier to $1.329 billion, ahead of the consensus estimate of $1.223 billion.

**Price Action:**

-   UnitedHealth shares slipped 0.01% to close at $375.21 on Thursday.
-   Goldman Sachs shares gained 1.4% to close at $951.47 during the session.
-   Teradyne shares surged 3.5% to settle at $353.13 on Thursday.

*Photo via Shutterstock*

### Related Stocks

- [GS-D.US](https://longbridge.com/en/quote/GS-D.US.md)
- [TER.US](https://longbridge.com/en/quote/TER.US.md)
- [GS-C.US](https://longbridge.com/en/quote/GS-C.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [GS-A.US](https://longbridge.com/en/quote/GS-A.US.md)
- [UNH.US](https://longbridge.com/en/quote/UNH.US.md)
- [UNHG.US](https://longbridge.com/en/quote/UNHG.US.md)
- [UNHU.US](https://longbridge.com/en/quote/UNHU.US.md)
- [UNHW.US](https://longbridge.com/en/quote/UNHW.US.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [VRTS.US](https://longbridge.com/en/quote/VRTS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)

## Related News & Research

- [Suze Orman warned 390,000 people their Medicare plans are shutting down, then CNBC called the same stock a turnaround](https://longbridge.com/en/news/304835305.md)
- [Goldman Sachs promotes 109 bankers to partner ranks but omits demographic data](https://longbridge.com/en/news/304509486.md)
- [Plenty Of Exposure, Zero Conviction: Goldman's Traders Dissect All The Latest Hedge Fund Positioning And Flows](https://longbridge.com/en/news/304901926.md)
- [UnitedHealth Group (UNH) Draws Fresh Breakup Calls After $3.3 Billion Deal քնն](https://longbridge.com/en/news/304417452.md)
- [Goldman Sachs names five Swiss among 109 new partners](https://longbridge.com/en/news/304835387.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**